Form 4: Organon & Co. CFO Matthew Walsh Reports Stock Transactions
SEC Form 4 Filing
Chief Financial Officer of Organon & Co., Matthew M. Walsh, reports the vesting and subsequent sale of restricted stock units.
Summary
- On February 28, 2024, Matthew M. Walsh, the Chief Financial Officer of Organon & Co., reported transactions involving Organon & Co. common stock.
- Walsh converted 33,044 restricted stock units into common stock.
- Simultaneously, Walsh disposed of 33,044 shares of common stock.
- Additionally, Walsh disposed of 11,393 shares to cover tax obligations at a price of $18.04 per share.
- Following these transactions, Walsh directly owns 74,062 shares of Organon & Co. common stock.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions by an executive, with no inherent positive or negative implications for the company's performance.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common practice and required by the SEC to ensure transparency and prevent insider trading.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership by a key executive, but the overall impact is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 12/31/2023 | Restricted Stock Units vested |
| 02/28/2024 | Date of stock transactions: conversion of restricted stock units, disposal of shares, and tax obligation fulfillment |
| 03/01/2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.